Atossa Therapeutics is advancing ESR1-mutation research to address endocrine resistance in ER-positive breast cancer, centering on investigational therapy (Z)-e

Atossa Therapeutics is advancing ESR1-mutation research to address endocrine resistance in ER-positive breast cancer, centering on investigational therapy (Z)-endoxifen. The effort builds on prior KARISMA and ASCO 2026 updates and a broader pipeline push.